drug|rank|Phase II result
temozolomide|90|positive
vorinostat|44|modest single-agent activity [1]
sorafenib|34|limited efficacy in combination with temsirolimus [2] and bevacizumab [3]
capecitabine|266|NA
ritonavir|106|modest efficacy [4]
bevacizumab|330|positive
valganciclovir|1273|increase median overall survival [5]
cyclophosphamide|88|modest efficacy [6]
bortezomib|14|limited efficacy in combination with bevacizumab [7] and vorinostat [8]
topotecan|143|modest activity in recurrent glioblastoma [9] and no statistically significant survival advantage combined with cranial radiation [10]
sunitinib|45|did not prolong progression-free survival [11]
imatinib|31|glioblastoma multiforme proliferation and survival mechanisms are not substantially reduced [12]
gefitinib|46|not associated with significant improvement in overall survival or progression-free survival [13]
carmustine|144|effective and feasible [14]
pioglitazone|35|moderately active [15]
mercaptopurine|268|improved survival with other four drugs [16]
fludarabine|112|terminated
etoposide|19|has some activity with two other drugs [17]
nelfinavir|279|NA
celecoxib|47|did not meet the primary end point of improvement of 4-month PFS [18]
chloroquine|104|NA
everolimus|121|initial antiproliferative effect in a genetically distinct subset of tumors, no survival benefit compared with historical controls treated with conventional therapy [19]
dasatinib|41|Intraparticipant dose escalation was feasible, but dasatinib was ineffective in recurrent GBM [20]
sirolimus|9|Tumor markers failed to show an association with PFS except for increased pAKT expression [21]
lenalidomide|169|NA
dexamethasone|4|NA
paclitaxel|30|minimal activity [22]
isotretinoin|102|do not establish a benefit for the combination with three other drugs [23]
irinotecan|59|Bevacizumab and irinotecan is an effective treatment [24]
memantine|505|terminated
erlotinib|68|Erlotinib co administered with RT and temozolomide was not efficacious [25]
lomustine|1069|The combination of lomustine, TMZ, and radiotherapy yielded promising survival data in patients with newly diagnosed GBM [26]
streptozocin|76|NA
hydroxyurea|56|did not show clinically meaningful anti-tumour activity [27]
vandetanib|96|Vandetanib did not have significant activity in unselected patients with recurrent malignant glioma [28]
temsirolimus|214|failed to detect activity [29]
lopinavir|222|terminated
thioguanine|216|combination with four other drugs appears to be active [30]
carboplatin|92|combination with two other drugs show modest activity [31]
imiquimod|161|NA
aminolevulinic acid|629|NA

[1] Galanis, Evanthia, et al. "Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study." Journal of Clinical Oncology 27.12 (2009): 2052-2058.
[2] Lee, Eudocia Q., et al. "Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02." Neuro-oncology 14.12 (2012): 1511-1518.
[3] Galanis, Evanthia, et al. "Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial." Clinical Cancer Research 19.17 (2013): 4816-4823.
[4] Ahluwalia, Manmeet S., et al. "Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas." Journal of neuro-oncology 102.2 (2011): 317-321.
[5] Stragliotto, Giuseppe, et al. "Effects of valganciclovir as an add‐on therapy in patients with cytomegalovirus‐positive glioblastoma: A randomized, double‐blind, hypothesis‐generating study." International Journal of Cancer 133.5 (2013): 1204-1213.
[6] Chamberlain, Marc C., and Denice D. Tsao‐Wei. "Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide‐refractory glioblastoma multiforme." Cancer 100.6 (2004): 1213-1220.
[7] Bota, D. A., et al. "Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma." ASCO Annual Meeting Proceedings. Vol. 29. No. 15_suppl. 2011.
[8] Friday, Bret B., et al. "Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study." Neuro-oncology (2011): nor198.
[9] Macdonald, D., et al. "Phase II study of topotecan in patients with recurrent malignant glioma." Annals of oncology 7.2 (1996): 205-207.
[10] Fisher, Barbara, et al. "Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513." International Journal of Radiation Oncology* Biology* Physics 53.4 (2002): 980-986.
[11] Kreisl, Teri Nguyen, et al. "Continuous daily sunitinib for recurrent glioblastoma." Journal of neuro-oncology 111.1 (2013): 41-48.
[12] Razis, Evangelia, et al. "Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment." Clinical Cancer Research 15.19 (2009): 6258-6266.
[13] Uhm, Joon H., et al. "Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074." International Journal of Radiation Oncology* Biology* Physics 80.2 (2011): 347-353.
[14] Lassen, Ulrik, et al. "Treatment of newly diagnosed glioblastoma multiforme with carmustine, cisplatin and etoposide followed by radiotherapy. A phase II study." Journal of neuro-oncology 43.2 (1999): 161-166.
[15] Hau, Peter, et al. "Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas–a phase II study." Oncology 73.1-2 (2008): 21-25.
[16] Levin, V. A., et al. "Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas." Cancer treatment reports 70.11 (1986): 1271-1274.
[17] Aoki, Tomokazu, et al. "Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme: Clinical article." Journal of neurosurgery 112.1 (2010): 50-56.
[18] Kesari, Santosh, et al. "Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults." Neuro-oncology 10.3 (2008): 300-308.
[19] Ma, Daniel J., et al. "A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K." Neuro-oncology (2014): nou328.
[20] Lassman, Andrew B., et al. "Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)." Neuro-oncology (2015): nov011.
[21] Reardon, David A., et al. "Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma." Journal of neuro-oncology 96.2 (2010): 219-230.
[22] Fetell, Michael R., et al. "Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium." Journal of clinical oncology 15.9 (1997): 3121-3128.
[23] Penas-Prado, Marta, et al. "Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma." Neuro-oncology (2014): nou155.
[24] Vredenburgh, James J., et al. "Bevacizumab plus irinotecan in recurrent glioblastoma multiforme." Journal of Clinical Oncology 25.30 (2007): 4722-4729.
[25] Peereboom, David M., et al. "Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme." Journal of neuro-oncology 98.1 (2010): 93-99.
[26] Gallego, O. "Nonsurgical treatment of recurrent glioblastoma." Current Oncology 22.4 (2015): e273.
[27] Reardon, D. A., et al. "Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma." British journal of cancer 101.12 (2009): 1995-2004.
[28] Kreisl, Teri N., et al. "A phase I/II trial of vandetanib for patients with recurrent malignant glioma." Neuro-oncology 14.12 (2012): 1519-152.
[29] Lassen, Ulrik, et al. "Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme." Anticancer research 33.4 (2013): 1657-1660.
[30] Levin, V. A., et al. "Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children." Neuro-oncology 2.1 (2000): 22-28.
[31] Reardon, David A., et al. "Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy." Cancer 117.23 (2011): 5351-5358.

*Note: NA means the study result is not available. For example, a study has not been opened yet.